Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

125 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-01

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This safety pilot study evaluates the effect of hydroxychloroquine on preventing recurrent cardiovascular events among myocardial infarction patients. Half of the participants will receive hydroxychloroquine, whereas the other half will receive placebo during six months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy

NCT05961202

Inflammatory Cardiomyopathy Myocarditis

RECRUITING PHASE2/PHASE3

Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts

NCT04652648

Covid19 Hydroxychloroquine Coronavirus Infection +2 more

COMPLETED PHASE4

Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease.

NCT02874287

Coronary Artery Disease

COMPLETED PHASE4

Hydroxychloroquine in Colchicine-Resistant Glucocorticoid-Dependent Idiopathic Recurrent Pericarditis

NCT05737680

Pericarditis Idiopathic Recurrent

UNKNOWN PHASE3

Anti-Inflammatory Drug and Endothelial Function

NCT04161339

Cardiovascular Diseases Endothelial Dysfunction Sleep Apnea +2 more

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Anti-rheumatic medications decrease cardiovascular mortality in rheumatoid arthritis patients, based mainly on their anti-inflammatory effect. No studies have addressed their effect on preventing recurrent cardiovascular events among non-rheumatic patients.

In the pilot phase 200 myocardial infarction patients will be recruited during their index visit to the study hospitals. Patients will be randomized after initial coronary angiography to receive either hydroxychloroquine 300 mg a day or placebo during six months. Patients will be followed up until 12 months at four visits. Visit one is at doctor´s office at 3 to 5 weeks from the day of recruitment. Visit two is at study nurse´s office at 5.5 to 6 months. Visit three is a phone interview by the study nurse at 8.5 to 9.5 months. Visit four at 11.5 to 12.5 months is at doctor´s office.

This study evaluates the safety of hydroxychloroquine in the setting of myocardial infarction, and whether hydroxychloroquine treatment could reduce the incidence of recurrent cardiovascular events among myocardial infarction patients. Furthermore, the effect of hydroxychloroquine on cardiovascular risk factors and systemic inflammation parameters will be studied. In a subgroup of 40 patients, the effect of hydroxychloroquine on aortic inflammation will be assessed by PET/CT scan.

If this safety pilot study with 200 patients proves successful (i.e. no major complications), 2500 patients will be recruited in additional centers in Finland and the Nordic Countries.

Orion Pharma provides the active hydroxychloroquine tablet (Oxiklorin) but provides no other assistance or funding for the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction Acute Coronary Syndrome Inflammation Hydroxychloroquine Antirheumatic Agents Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hydroxychloroquine

Hydroxychloroquine 300 mg tablet by mouth daily for 6 months. Patients under the weight of 60 kg: hydroxychloroquine 300 mg tablet daily for 5 days per week for 6 months.

Group Type EXPERIMENTAL

Hydroxychloroquine

Intervention Type DRUG

Placebo

Placebo tablet by mouth daily for 6 months. Patients under the weight of 60 kg: placebo tablet daily for 5 days per week for 6 months.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydroxychloroquine

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Oxiklorin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients must have high-sensitivity troponin or CKMB above the upper limit of normal with at least one of the following criteria:

1. Anginal symptoms suggestive of cardiac ischemia

1. Accelerating pattern of anginal pain (episodes of angina that have at least 5 minutes duration and are more frequent, severe, longer in duration and/or precipitated by less exertion).
2. Prolonged (\>20 minutes) or recurrent anginal pain at rest or with minimal effort.
3. Anginal pain at rest or with minimal exertion, and at least 20 minutes of duration, occurring \>48 hours after an acute Q-wave myocardial infarction.
2. ECG criteria

1. New, persistent or transient ST-segment depression \>0,1 mV (0,08 seconds after the J-point) in at least 2 extremity leads or 3 precordial leads.
2. New, persistent or transient ST-segment elevation in two contiguous leads ≥0.2 mV in men or ≥0.15 mV in women in leads V2-V3, and/or ≥0.1 mV in other leads.

Patients will be enrolled within 96 hours of coronary angiography

Exclusion Criteria

* Contraindication for hydroxychloroquine (porphyria, psoriasis, retinopathy, hypersensitivity)
* Rheumatoid arthritis or other rheumatic disease
* Significant neuropathy of any cause
* Cardiomyopathy (diagnosed before the onset of index hospitalization)
* Muscle disease (that could worsen by the use of hydroxychloroquine)
* Pregnant or nursing women, and women of childbearing potential without efficient contraceptives.
* Angina precipitated by obvious provoking factors
* Prolonged ECG's corrected QT interval (\>480 ms)
* Ongoing antibiotic therapy of any duration
* Uncontrolled severe cardiac arrhythmia resulting in hemodynamic instability
* Severe hepatic failure (alanine transaminase or gamma-glutamyltransferase ≥2 times above normal limits or international normalized ratio (INR) \>1,5 and patient not using warfarin, and due to other than cardiac reasons).
* Renal failure, glomerular filtration rate \<50 ml/min/1,73m2
* Hemoglobin \<100 g/l (if not possible to correct with transfusion)
* Planned percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
* Index myocardial infarction due to PCI or CABG restenosis.
* Inability to interpret ST-T segment changes on ECG (e.g. complete left bundle branch block or paced rhythm)
* Prior thrombolytic therapy (within 12 hours)
* Inability to give informed consent
* Fulminant vomiting or other disability to give oral medication
* Over 80 years of age
* Life expectancy less than one year
* Receiving another investigational drug within 4 weeks prior to the study. (Patients who have participated in investigational trials before the 4-week time period may be randomized as long as they have reached the primary endpoint).
* Patients with any other medical condition which, in the investigator's opinion, would interfere with optimal participation in the study or produce a significant risk to the patient

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No